Ampio Reports Manuscript on the Mechanisms of Action (MOA) for Ampion™ accepted for Publication in Clinical and Experimental Rheumatology
Published: Sep 13, 2018
ENGLEWOOD, Colo., /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced a basic science manuscript entitled "Clinically relevant re-differentiation of fibroblast-like chondrocytes into functional chondrocytes by the low molecular weight fraction of human serum albumin," authored by Melissa Hausburg, PhD; Elizabeth Frederick, PhD; Patrick McNair, MD, John Schwappach, MD, Kaysie L. Banton, MD, Michael Roshon, MD-PhD, Mark J. Lieser, MD, David L. Acuna, MD, Rahul R. Banerjee, MD, David Bar-Or, MD was accepted for publication in Clinical and Experimental Rheumatology. This is the 11th peer-reviewed publication that explores how multiple, interrelated, molecular mechanisms work synergistically to provide patients severely afflicted by Osteoarthritis of the knee (OAK) not only with near-term pain relief and improved function but also in vitro evidence of potentially disease-modifying regeneration of cartilage.
Dr. David Bar-Or, a member of Ampio's Scientific Advisory Board (SAB) and senior author, explains "This paper provides preliminary evidence that Ampion™ may trigger and support new cartilage growth in joints affected by Osteoarthritis (OA). As OA develops, the cells that make up cartilage, chondrocytes, begin to malfunction, contributing to cartilage breakdown. If the malfunctioning chondrocytes re-started normal function, the breakdown of existing cartilage would cease, and new cartilage may form, contributing to increased joint function".
Dr. Bar-Or continues, "In the work reported in this manuscript, we treated malfunctioning chondrocytes in vitro multiple times with Ampion over a period of either one or two weeks. We show that Ampion treatment of chondrocytes suppresses the production of IL-6, a pro-inflammatory cytokine associated with OA progression. Furthermore, Ampion induced critical cartilage proteins, SOX9, COL2, and aggrecan, which support functional chondrocytes. In cartilage, aggrecan bound to glycosaminoglycans enables cartilage to bear high compressive loads, and we were able to ascertain that newly formed aggrecan was integrated into a matrix with increased glycosaminoglycans in chondrocytes treated with Ampion.
Ampion, a derivative of human serum albumin, has also been shown to be extremely safe. There have been no adverse drug-related side effects reported in multiple clinical trials. In addition to the beneficial effects on pain and function in OAK patients, there is preliminary evidence that Ampion treatment may delay the time for total knee replacement in patients with OA and may prevent post-traumatic OA, acting as a disease-modifying agent when used after traumatic joint injury. Since all joints can be affected by acute injury to the articular cartilage, these data support prophylactic intra-articular treatment with Ampion following traumatic injury for OA prevention."
A link to the full manuscript will be made available when it is published online.
Regulatory Exclusivity and IP protection:
About Ampio Pharmaceuticals
View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-reports-manuscript-on-the-mechanisms-of-action-moa-for-ampion-accepted-for-publication-in-clinical-and-experimental-rheumatology-300711858.html
SOURCE Ampio Pharmaceuticals, Inc.
Company Codes: AMEX:AMPE